IPo

• Ценовой диапазон Предложения установлен между 85 руб. и 105 руб. за Акцию.

• Продающими акционерами выступают ПАО АФК «Система» (далее – «Система»), Российско-китайский инвестиционный фонд (РКИФ) через инвестиционные компании Floette Holdings Limited и Exarzo Holdings Limited, а также некоторые индивидуальные акционеры, в том числе некоторые представители менеджмента Компании и «Системы» (совместно – «Продающие акционеры»).

• Ожидается, что Продающие акционеры продадут до 247,9 млн Акций (включая опцион дополнительного размещения), что в рамках ценового диапазона соответствует объему Предложения от 21,1 млрд руб. до 26,0 млрд руб. и оценке Компании от 62,8 млрд руб. до 77,6 млрд руб.

Upcoming IPOs:

• January 26: AnaptysBio (ANAB)  — The biotech developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology is expected to price its 4.0 million share IPO within a range of $14-$16.

• January 26: ObsEva (OBSV)  — The clinical-stage biopharmaceutical company developing therapeutics for conditions that compromise a woman's reproductive health is expected to price its 6.5 million share IPO within a range of $14-$16.

• January 27: JELD-WEN (JELD)  — The leading door and window manufacturer is expected to price its 25.0 million share IPO within a range of $16-$18.

• January 27: Jagged Peak Energy (JAG)  — The oil & natural gas company focused on acquiring & developing unconventional assets in Southern Delaware Basin is expected to price its 38.2 million share IPO within a range of 16-$18.

• January 27: REV Group (REVG)  — The designer, manufacturer, and distributor of specialty vehicles & aftermarket parts is expected to price its 12.5 million share IPO within a range of $19-$21.

• January 27: Jounce Therapeutics (JNCE)  — The clinical stage immunotherapy focused on transforming treatment of cancer by enabling immune system to attack tumors is expected to price its 5.4 million share IPO within a range of $13-$15.

• January 27: Visterra (VIST)  — The clinical-stage biopharma focused on designing anti-body-based therapies intended to be as effective as single-dose administration is expected to price its 3.9 million share IPO within a range of $12-$14.